Custirsen does NOT significantly extend survival in men with mCRPC

OncoGenex and Teva stated earlier today that the addition of custirsen (OGX-011) to docetaxel + prednisone did not demonstrate any significant effect on the overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC).

The SYNERGY trial was a randomized, open-label, two-arm, Phase III study in which men with mCRPC were treated with either standard first-line chemotherapy (docetaxel+ prednisone) or with the investigational combination of docetaxel+ prednisone + custirsen.

According to the companies’ joint media release, “the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival.”

The median overall survival of patients being treated with the custirsen combination was 23.4 months as compared to 22.2 months for the patients receiving standard chemotherapy with docetaxel + prednisone. This difference was not statistically significant.

Full efficacy and safety data from the SYNERGY is going to be submitted for presentation at an upcoming scientific conference.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: